Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age
Background - Empagliflozin reduces cardiovascular death (CVD) or heart failure (HF) hospitalization (HFH) in patients with HF and preserved ejection fraction. Treatment effects and safety in relation to age have not been studied. - Objectives - The purpose of this study was to evaluate the interplay...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
5 July 2022
|
| In: |
Journal of the American College of Cardiology
Year: 2022, Jahrgang: 80, Heft: 1, Pages: 1-18 |
| ISSN: | 1558-3597 |
| DOI: | 10.1016/j.jacc.2022.04.040 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.jacc.2022.04.040 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0735109722049373 
|
| Verfasserangaben: | Michael Böhm, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Amr Abdin, Felix Mahfoud, Martina Brueckmann, Nicholas D. Gollop, Tomoko Iwata, Piotr Ponikowski, Christoph Wanner, Faiez Zannad, Milton Packer, Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Committees and Investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1902224523 | ||
| 003 | DE-627 | ||
| 005 | 20241205171148.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240910s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacc.2022.04.040 |2 doi | |
| 035 | |a (DE-627)1902224523 | ||
| 035 | |a (DE-599)KXP1902224523 | ||
| 035 | |a (OCoLC)1475311356 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Böhm, Michael |d 1958- |e VerfasserIn |0 (DE-588)1096256169 |0 (DE-627)856690694 |0 (DE-576)467967482 |4 aut | |
| 245 | 1 | 0 | |a Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age |c Michael Böhm, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Amr Abdin, Felix Mahfoud, Martina Brueckmann, Nicholas D. Gollop, Tomoko Iwata, Piotr Ponikowski, Christoph Wanner, Faiez Zannad, Milton Packer, Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Committees and Investigators |
| 264 | 1 | |c 5 July 2022 | |
| 300 | |a 18 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 27. Juni 2022, Artikelversion: 27. Juni 2022 | ||
| 500 | |a Gesehen am 10.09.2024 | ||
| 520 | |a Background - Empagliflozin reduces cardiovascular death (CVD) or heart failure (HF) hospitalization (HFH) in patients with HF and preserved ejection fraction. Treatment effects and safety in relation to age have not been studied. - Objectives - The purpose of this study was to evaluate the interplay of age and empagliflozin effects in EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction). - Methods - We grouped patients (n = 5,988) according to their baseline age (<65 years [n = 1,199], 65-74 years [n = 2,214], 75-79 years [n = 1,276], ≥80 years [n = 1,299]). We explored the influence of age on empagliflozin effects on CVD or HFH (primary outcome), total HFH, rate of decline in estimated glomerular filtration rate, health-related quality of life with the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score, and frequency of adverse events. - Results - Considering only patients on placebo, the incidence of primary outcomes (P trend = 0.02) and CVD (P trend = 0.003) increased with age. Empagliflozin reduced primary outcomes (P trend = 0.33), first HFH (P trend = 0.22), and first and recurrent HFH (P trend = 0.11) across all age groups with an effect being similar at ≥75 years (P interaction = 0.22) or >80 years (P interaction = 0.51). Empagliflozin improved Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score at week 52 and attenuated the decline of estimated glomerular filtration rate without age interaction (P = 0.48 and P = 0.32, respectively). There were no clinically relevant differences in adverse events between empagliflozin and placebo across the age groups. - Conclusions - Empagliflozin reduced primary outcomes and first and recurrent HFH and improved symptoms across a broad age spectrum. High age was not associated with reduced efficacy or meaningful intolerability. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction [EMPEROR-Preserved]; NCT0305951) | ||
| 650 | 4 | |a age | |
| 650 | 4 | |a cardiovascular outcomes | |
| 650 | 4 | |a empagliflozin | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a kidney function | |
| 700 | 1 | |a Butler, Javed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Filippatos, Gerasimos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ferreira, João Pedro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pocock, Stuart J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Abdin, Amr |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mahfoud, Felix |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Gollop, Nicholas D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Iwata, Tomoko |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ponikowski, Piotr |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wanner, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zannad, Faiez |e VerfasserIn |4 aut | |
| 700 | 1 | |a Packer, Milton |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anker, Stefan D. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a American College of Cardiology |t Journal of the American College of Cardiology |d New York, NY : Elsevier, 1983 |g 80(2022), 1, Seite 1-18 |h Online-Ressource |w (DE-627)266884717 |w (DE-600)1468327-1 |w (DE-576)099603837 |x 1558-3597 |7 nnas |
| 773 | 1 | 8 | |g volume:80 |g year:2022 |g number:1 |g pages:1-18 |g extent:18 |a Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jacc.2022.04.040 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0735109722049373 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240910 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |d 61000 |e 60000PB121145069 |e 61000PB121145069 |k 0/60000/ |k 1/60000/61000/ |p 8 | ||
| 999 | |a KXP-PPN1902224523 |e 4578402622 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"id":{"eki":["1902224523"],"doi":["10.1016/j.jacc.2022.04.040"]},"physDesc":[{"extent":"18 S."}],"recId":"1902224523","note":["Online verfügbar: 27. Juni 2022, Artikelversion: 27. Juni 2022","Gesehen am 10.09.2024"],"title":[{"title":"Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age","title_sort":"Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age"}],"person":[{"display":"Böhm, Michael","family":"Böhm","roleDisplay":"VerfasserIn","given":"Michael","role":"aut"},{"role":"aut","given":"Javed","display":"Butler, Javed","family":"Butler","roleDisplay":"VerfasserIn"},{"family":"Filippatos","display":"Filippatos, Gerasimos","roleDisplay":"VerfasserIn","given":"Gerasimos","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Ferreira, João Pedro","family":"Ferreira","given":"João Pedro","role":"aut"},{"family":"Pocock","display":"Pocock, Stuart J.","roleDisplay":"VerfasserIn","given":"Stuart J.","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Abdin","display":"Abdin, Amr","role":"aut","given":"Amr"},{"role":"aut","given":"Felix","display":"Mahfoud, Felix","family":"Mahfoud","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Martina","display":"Brückmann, Martina","family":"Brückmann","roleDisplay":"VerfasserIn"},{"given":"Nicholas D.","role":"aut","family":"Gollop","display":"Gollop, Nicholas D.","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Tomoko","family":"Iwata","display":"Iwata, Tomoko","roleDisplay":"VerfasserIn"},{"family":"Ponikowski","display":"Ponikowski, Piotr","roleDisplay":"VerfasserIn","role":"aut","given":"Piotr"},{"role":"aut","given":"Christoph","display":"Wanner, Christoph","family":"Wanner","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Zannad","display":"Zannad, Faiez","role":"aut","given":"Faiez"},{"family":"Packer","display":"Packer, Milton","roleDisplay":"VerfasserIn","given":"Milton","role":"aut"},{"given":"Stefan D.","role":"aut","family":"Anker","display":"Anker, Stefan D.","roleDisplay":"VerfasserIn"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"5 July 2022"}],"name":{"displayForm":["Michael Böhm, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Amr Abdin, Felix Mahfoud, Martina Brueckmann, Nicholas D. Gollop, Tomoko Iwata, Piotr Ponikowski, Christoph Wanner, Faiez Zannad, Milton Packer, Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Committees and Investigators"]},"relHost":[{"disp":"American College of CardiologyJournal of the American College of Cardiology","pubHistory":["1.1983 -"],"origin":[{"dateIssuedKey":"1983","publisherPlace":"New York, NY ; New York, NY","publisher":"Elsevier ; American College of Cardiology","dateIssuedDisp":"1983-"}],"corporate":[{"role":"aut","display":"American College of Cardiology","roleDisplay":"VerfasserIn"}],"part":{"volume":"80","pages":"1-18","year":"2022","extent":"18","issue":"1","text":"80(2022), 1, Seite 1-18"},"titleAlt":[{"title":"JACC"}],"recId":"266884717","physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"id":{"eki":["266884717"],"zdb":["1468327-1"],"issn":["1558-3597"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title_sort":"Journal of the American College of Cardiology","title":"Journal of the American College of Cardiology","subtitle":"JACC"}],"note":["Gesehen am 13.11.25","Ungezählte Beil.: Supplement"]}]} | ||
| SRT | |a BOEHMMICHAEMPAGLIFLO5202 | ||